Clinical trials: Posttraumatic Stress
Posttraumatic Stress Disorder
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
The goal of this clinical trial is to compare full dose MDMA-assisted therapy to placebo with therapy in participants with chronic, treatment-resistant PTSD.
- Trial name
- NCT01958593
- Testing
- Midomafetamine HCl, Psychotherapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with at least severe PTSD.
- Trial name
- NCT03485287
- Testing
- Midomafetamine HCl, Manualized therapy
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD.
- Trial name
- NCT01211405
- Testing
- Low dose MDMA-assisted therapy, Medium dose MDMA-assisted therapy, Full dose MDMA-assisted therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD).
- Trial name
- NCT00090064
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Resilient Pharmaceuticals
Post Traumatic Stress Disorder
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
- Trial name
- NCT05178316
- Testing
- JZP150
- Where
- 52 sites in United States
- Volunteers
- 282 people
- Sponsor
- Jazz Pharmaceuticals
Posttraumatic Stress Disorder
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
This study will consist of a single session of MDMA-assisted therapy with a full dose of MDMA for people who took part in a study of MDMA-assisted therapy in people with posttraumatic stress disorder (PTSD) whose PTSD symptoms…
- Trial name
- NCT01458327
- Testing
- Midomafetamine, Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
- Trial name
- NCT00353938
- Testing
- 3,4-methylenedioxymethamphetamine (125 mg), 3,4-methyelendioxymethamphetamine (25 mg), Therapy
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.
- Trial name
- MAPPUSX (NCT04714359)
- Testing
- Midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD).
- Trial name
- NCT01339689
- Testing
- Ganaxolone
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Marinus Pharmaceuticals
Posttraumatic Stress Disorder
A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients
This is a multicenter retrospective study to investigate the dosage regimens of sertraline in the treatment of Posttraumatic Stress Disorder (PTSD) under current medical practice and the efficacy and safety of this drug in…
- Trial name
- NCT01607593
- Testing
- sertraline (Zoloft)
- Where
- 4 sites in Japan
- Volunteers
- 123 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Posttraumatic Stress Disorder
Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel
The goal of this clinical trial is to learn if MDMA-assisted therapy can treat PTSD in participants with PTSD. Researchers will compare two sessions of MDMA-assisted therapy with two sessions of low dose (active placebo)…
- Trial name
- NCT00402298
- Testing
- Full Dose Midomafetamine HCl, Low Dose Midomafetamine HCl
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Resilient Pharmaceuticals
Post-Traumatic Stress Disorder, Stress Disorders, Post-Traumatic
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
This is a single-blind, placebo-controlled, parallel group study to evaluate the efficacy of BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily…
- Trial name
- NCT00557622
- Testing
- paroxetine
- Where
- 9 sites in Japan
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT04030169
- Testing
- Midomafetamine HCl
- Where
- 6 sites in Czechia, Germany and 3 more
- Volunteers
- 21 people
- Sponsor
- MAPS Europe B.V.
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
- Trial name
- NCT03282123
- Testing
- Midomafetamine, Manualized therapy
- Where
- 12 sites in United States
- Volunteers
- 38 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least moderate PTSD.
- Trial name
- NCT04077437
- Testing
- Therapy, Midomafetamine
- Where
- 14 sites in United States, Israel
- Volunteers
- 121 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least severe PTSD. The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD…
- Trial name
- NCT03537014
- Testing
- Therapy, midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Resilient Pharmaceuticals